Payment overview · 2025
General Payments
$827.90
60 reported records · 16 companies
Healthcare provider profile · identity verified
Bobby Anthony Wrights, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1700814050
Verified facts
What the public records show
CMS Open Payments records show Bobby Anthony Wrights, MD received $827.90 in general payments during 2025 across 60 reported records.
Amgen Inc. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 317 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.88 | 23.2% | 29 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $173.25 | 20.9% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.27 | 10.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.23 | 9.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.49 | 6.2% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $39.81 | 4.8% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $36.48 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.10 | 3.0% | 1 | 2025 |
| BSN Medical Inc | Unresolved — no canonical attribution shown | $22.62 | 2.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.06 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.99 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.85 | 2.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.61 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.01 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.25 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $827.90 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $191.88 | 29 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $157.98 | 24 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $95.46 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $83.27 | 4 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $54.01 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.90 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $36.48 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $36.48 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| CUTIMED Normalized: cutimed |
Device | BSN Medical Inc | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 173 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 317 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
99 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
317 | 68 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1015 | 327 |
| Amlodipine Besylate | Amlodipine Besylate | 929 | 285 |
| Losartan Potassium | Losartan Potassium | 623 | 186 |
| Carvedilol | Carvedilol | 336 | 113 |
| Metformin Hcl | Metformin Hcl | 332 | 117 |
| Farxiga | Dapagliflozin Propanediol | 317 | 68 |
| Omeprazole | Omeprazole | 294 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 96 |
| Meloxicam | Meloxicam | 265 | 87 |
| Tizanidine Hcl | Tizanidine Hcl | 263 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 261 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 69 |
| Ozempic | Semaglutide | 203 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 57 |
| Telmisartan | Telmisartan | 189 | 58 |
| Trazodone Hcl | Trazodone Hcl | 184 | 57 |
| Mounjaro | Tirzepatide | 182 | 31 |
| Eliquis | Apixaban | 173 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 45 |
| Potassium Chloride | Potassium Chloride | 149 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 36 |
| Jardiance | Empagliflozin | 113 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 33 |
| Xarelto | Rivaroxaban | 110 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 106 | 33 |
| Alendronate Sodium | Alendronate Sodium | 104 | 40 |
| Allopurinol | Allopurinol | 99 | 33 |
| Atenolol | Atenolol | 99 | 28 |
| Linzess | Linaclotide | 99 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 33 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 98 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 34 |
| Kerendia | Finerenone | 88 | 18 |
| Methylprednisolone | Methylprednisolone | 83 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Furosemide | Furosemide | 79 | 30 |
| Tramadol Hcl | Tramadol Hcl | 73 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 25 |
| Metformin Hcl Er | Metformin Hcl | 66 | 20 |
| Mometasone Furoate | Mometasone Furoate | 66 | 33 |
| Sertraline Hcl | Sertraline Hcl | 58 | 15 |
| Simvastatin | Simvastatin | 58 | 18 |
| Trulicity | Dulaglutide | 58 | 11 |
| Lisinopril | Lisinopril | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 57 | 13 |
| Famotidine | Famotidine | 55 | 20 |
| Ezetimibe | Ezetimibe | 54 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | suppressed |
| Entresto | Sacubitril/Valsartan | 46 | 16 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Gabapentin | Gabapentin | 43 | 15 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 13 |
| Labetalol Hcl | Labetalol Hcl | 38 | 12 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Vascepa | Icosapent Ethyl | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 22 |
| Memantine Hcl | Memantine Hcl | 29 | 12 |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | 11 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | 15 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 16 |
| Glipizide | Glipizide | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Clonidine | Clonidine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $827.90 · 60 records | Amgen Inc. | APLIGRAF, AREXVY, BREZTRI, COLLAGENASE SANTYL, CUTIMED, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Flexitouch Plus, Kerendia, Korlym, LEQVIO, NOVACHOR, NURTEC ODT, Nimbl, OTEZLA, PURAPLY WOUND MATRIX, RENASYS TOUCH, REPATHA, SHINGRIX, TEFLARO, VOQUEZNA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error